Skip to main content

Chemspec highlight: Pharma outsourcing – best practices

3rd July 2018

Submitted by:

Andrew Warmington

“Fail early and fail cheap” – this was the key message from Dr Magid Abou-Gharbia of the Moulder Center for Drug Discovery Research at Temple University’s School of Pharmacy in Philadelphia, US.

The landscape is changing; small molecules currently represent around 75% of existing drugs, but companies are moving towards a 50/50 ratio of small to large molecules. In the last 80 years, the US Food and Drug Administration (FDA) has approved 1,607 drugs, comprising 246 biological drugs and 1,361 small molecule drugs, but there remain at least 5,000 drugable ‘targets’. Because it costs around US$2 billion to find a new drug, with the cost increasing in the late stages, it’s more financially savvy to fail early.

Drug discovery is “all about finding the right key for the lock” and personalised medicine is one such key, Abou-Gharbia says. Not all patients respond to drugs – sometimes only 38%, such as for depression, or 60% for asthma, 25% for cancer – but knowing the DNA means you can make a better drug. Personalised medicine increases the survival rate.

Gene therapy will provide the solution but it gained a bad reputation when Jesse Geisinger, a volunteer suffering from the rare metabolic disorder ornithine transcarbamylase (OTC) deficiency, died. The first death directly related to gene therapy, it “set back the therapy 30 years”, says Abou-Gharbia, but the FDA approved the first drug last year and has since approved more.

Nevertheless, the cost is huge, even if it provides a 100% cure. Gene bioengineering, such as CRISPR, which cuts out the ‘bad’ gene and inserts a ‘good’ one, offers hope, but there have been no human trials yet.

What makes a good CMO?

After Abou-Gharbia’s introduction, attention turned towards the question of what makes a ‘good’ contract manufacturing organisation (CMO). An impressive line up of pharma experts provided insights. “In a US$50 billion industry, speed is getting more critical. Good technical support, efficiency and a good chain supply is a must,” said Dr Lukas Utiger, division president, DPS & PDS North America, Patheon, ThermoFisher Scientific. Kimberly Lounds Foster, corporate vice president of global supply at Celgene, agreed, adding that efficient use of capital and sensible partnerships drive sustainability.

An important question is what the customer is looking to outsource, said Nick Shackley, vice president and innovator products and solutions at Johnson Matthey. Small companies have no capabilities, so technology plays an important part.

Furthermore, it is better to find a CMO specialised in the technology you’re looking for; ‘one stop shops’ do not provide a solution. Dr Rudolf Henko, CEO of Siegfried, said: “A one stop shop is a synonym for failure, for not knowing anything. You cannot be a master of everything – you have to strike a balance between competency and capturing everything.” Syed T Husain, chief commercial officer at Alcami, agreed: “An integrated, focused offering has been proven to be successful, not multiple business units.”

Five years from now, what will the CMO market look like? David Strohner, global director of external manufacturing and late development global procurement at Bristol-Myers Squibb, said the market today is highly fragmented and capacity is underused.

Utiger said that consolidation in the market will continue and around five large companies would comprise 80% of the market. But this consolidation will only occur in ‘mature’ therapies, Foster added. “The role of externalisation changes depending on small or large molecules and organisations good at clinical might not be good at something else,” she said.

Husain suggested companies take a ‘scaleability’ approach; a “me too” space does not add value to the industry, CMOs should scale up or branch out only when it is required. Henko concurred, adding that size is not the answer, that companies should try to reach “critical size” where they are effective and at the front of new technologies.

Finally, Rebecca Bishop, associate director of manufacturing procurement at Eli Lilly, said that the ‘Made in China’ initiative will increase CMOs in the country and that large CMOs around the globe will continue to grow, but Dr Joachim Kaus, VP chemical development and managing director at AMRI in Germany, said that the current trend towards ‘reshoring’ would continue, as customers withdraw from China to ensure a strong and stable supply chain.

Outsourcing risk

What about risk management? Is it possible to outsource risk entirely to a CMO? Not entirely, the experts concluded. While some experts, such as Strohner, said that trust in a CMO was key to mitigate risks, others suggested that drug development cannot be entirely risk free. “Two out of three active pharmaceutical ingredients (APIs) violate Lipinski’s ‘rule of five’,” said Henko. “It’s a fine art game getting it right – R&D efficiency is key and it is a big risk if not done properly.” 

Foster added that, while cell therapy innovators are moving at the speed of light to get technology approved and to market, they are not focusing on the ‘eco-system’. This is where the risk comes in. Shackley concluded that we need to help small biotechs with a risk strategy but the question is: how best can we do this?

Chemspec Europe was held in Cologne, Germany on 20-21 June.


 

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington